Lipid Regulators Market

The Lipid Regulators Market is valued at USD 12.11 Bn in 2026 and is projected to reach USD 17.3 Bn, growing at a CAGR of 5% by 2033.

Lipid Regulators Market Witnesses Robust Growth as Global Burden of Cardiovascular Diseases Rises

There has been a surge in demand for lipid regulators due to the frequency of disorders like dyslipidemia. Dyslipidemia, especially in smokers, raises the risk of smoking-related atherosclerosis, heart attacks, strokes, and other circulatory issues. The elderly population is also more vulnerable to cardiovascular illnesses. Lipid-altering drugs have been shown to lower cardiovascular risk in the elderly. North Africa, the Middle East, Central, and South Asia, and Eastern Europe had the highest prevalence rates of ischemic heart disease (IHD) worldwide in 2020, according to the 2022 American Heart Association (AHA) report. IHD affects approximately 244.1 million people worldwide. Due to the increasing prevalence of risk factors such as a sedentary lifestyle, smoking, obesity, hypertension, and diabetes, it is projected that the burden of cardiovascular diseases will continue to rise. As a result, the lipid regulators market is anticipated to develop throughout the forecast period due to an increase in the use of lipid regulators.

Lipid regulators are used to reducing cholesterol when there is an increase in obesity, which is likely to accelerate lipid regulators market growth during the forecast period. Between March 2017 and March 2020, 41.9% of Americans were obese, as per the statistics from the Centers for Disease Control and Prevention (CDC) that was updated in May 2022. In the U.S., the percentage of people who are obese climbed from 30.5 to 41.9%. During the same period, the prevalence of extreme obesity increased from 4.7% to 9.2%. Obesity is one of the major causes of chronic diseases both globally and in the United States, according to the CDC, and it is a primary cause of needless death in the country.

Lipid Regulators Market: COVID-19 Impact

Due to their health-promoting qualities, lipid-based supplements saw an increase in demand throughout the pandemic. For instance, the research described in the article titled "Lipids and COVID-19. The impact of lipid issues and statin use on patients with SARS-CoV-2 infection's prognosis" has demonstrated that COVID-19 infection affects the lipid profile, causing dyslipidemia, which may call for the proper medical care. Statin therapy has been regarded as an important approach to enhance COVID-19 results because of its antiviral, anti-inflammatory, immunomodulatory, and cardioprotective effects. Thus, as COVID-19 becomes more widespread, patients consume more lipid nutritional products. It allows patients to recover from COVID-19 infection more quickly, which benefits lipid regulators market growth.

Rising Elderly Population to Drive Lipid Regulators Market Growth

The lipid regulators market is anticipated to grow as the older population grows since they are more susceptible to chronic illnesses like cardiovascular disorders. The world's population of 65 years of age or older is expected to increase from 10% in 2022 to 16% in 2050, according to the World Aging Report 2022. Globally, the number of adults 65 and older is expected to increase significantly by 2050, surpassing the number of children under the age of five and those under the age of twelve. Therefore, it is anticipated that as the population ages, there will be greater demand for lipid regulators, which would further support market expansion throughout the projection period.

Use of Branded Statins to Drive Lipid Regulators Market

Branded statins are better at reducing LDL-cholesterol levels than other lipid-regulating medications. Atorvastatin, Fluvastatin, Pravastatin, Rosuvastatin, and Simvastatin are a few of the statins on the lipid regulators market. Consequently, it is anticipated that as the incidence of dyslipidemia rises, so will the demand for these statins. The incidence of dyslipidemia is also more likely to be higher in the diabetic population. In populations with illness, the statins reduce cholesterol levels by competitively inhibiting HMG-CoA reductase. According to the World Health Organization, there are more than 400 million diabetics worldwide, and the cost of treating them accounts for around 12% of all healthcare spending globally. Millions of people were impacted worldwide as it turned into a global epidemic. Type 1 diabetes accounts for 10% of all cases, with type 2 accounting for the remainder. Thus, an increase in the prevalence of dyslipidemia due to the rising prevalence of diabetes is possible, and this is anticipated to spur the growth throughout the forecast period.

Lack of Consumer Awareness to Limit Lipid Regulators Market Growth

Consumers are constraining the development of this industry in developing nations that are unaware of the health advantages of lipids regulators. It is due to the market experiencing restrictions due to the availability of substitute products and reduced penetration throughout the perspective period. According to estimates, the following factors would likely slow the expansion of the global lipid regulators market: unsuitability for patients with specific health conditions, high maturity among raw material suppliers, sustainability issues with fishing, and low catch limits. Rising technology and raw materials costs will challenge the market during the hypothetical timeframe.

Triglycerides Category Dominates Lipid Regulators Market with Rising Demand from End-use Sectors

The triglycerides category held the largest market share, and it is anticipated that it will continue to rule the market during the forecast period. Its large lipid regulators market share can be attributed to the rising demand from end-use sectors, including functional beverages and dietary supplements, for their derivatives, medium-chain triglycerides, and long-chain triglycerides. Since triglyceride lipids constitute a significant energy source, they are widely used in various functional foods and beverages. On the other hand, the phospholipids segment is anticipated to rise significantly throughout the forecast period due to its superior ability to distribute omega-3 fats throughout the body, making it a key component in creating functional foods and dietary supplements. Furthermore, it is projected that demand for phospholipids will increase internationally over the short term due to the growing usage of phospholipids in various pharmaceutical technologies as emulsifiers, wetting agents, and builders of micelles, liposomes, cubosomes, and other structures.

Food and Beverages Category to Dominate Lipid Regulators Market

The food & beverage category dominated the lipid regulators market in 2021. Due to the rapid population growth, the food and beverage business is expanding globally, which accounts for its large contribution. Due to their beneficial qualities as a rich source of vitamins and energy, lipids are mostly used to prepare functional food and beverages. The terrible COVID-19 condition and growing health risks have increased the demand for nutrient-rich foods and beverages. Additionally, because lipids are used in a growing number of pharmaceutical applications, including drug development, it is anticipated that demand for them will increase. In particular, it was an essential component in developing COVID-19 vaccines in 2021. In the pharmaceutical industry, they are regarded as essential excipients for creating the vast majority of dosage forms.

North America to Lead Lipid Regulators Market in Line with Rising Prevalence of Diabetes

Over the forecast period, it is anticipated that the North America lipid regulators market will account for the largest revenue share. The United States and Mexico are among the countries with the greatest prevalence of obesity and diabetes, according to OECD data released in May 2021. Additionally, type 2 diabetes, the most common form, is more likely to develop in those who are overweight or obese. Over the next few years, there will likely be an increase in demand for lipid regulators because having diabetes raises the risk of dyslipidemia. According to data from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) updated in December 2020, 34.2 million persons in the United States are expected to have diabetes or 10.5% of the country's population. The same source estimates that 26.9 million Americans of all ages (8.2% of the population of the United States) have diabetes. As a result, the rising prevalence of diabetes is anticipated to enhance the need for lipid regulators in the area, which is anticipated to spur market expansion throughout the projection period.

Asia Pacific lipid regulators market is anticipated to experience stable revenue growth throughout the forecast period. One reason for regional growth may be the rising incidence of cardiovascular disorders and greater knowledge of the advantages of employing lipid regulators. Furthermore, it is projected that rising disposable income levels in developing nations like China and India will support market expansion for the projection period. Due to their safety record compared to other formulations currently on the market, these goods are in greater demand throughout these locations due to regulatory bodies' regulations encouraging drug safety & efficacy. The region's  market is expected to increase favorably due to leading companies focusing more on potential pioneer markets in the Asia Pacific.

Global Lipid Regulators Market: Competitive Landscape

In May 2022, to lower low-density lipoprotein (LDL) cholesterol, Sun Pharmaceutical Industries Limited introduced Bempedoic Acid, a first-in-class oral medication, in India. Brillo was the name given to the medication by the business. Additionally, in December 2021, Leqvio (inclisiran), the first and only small interfering RNA (siRNA) treatment to lower low-density lipoprotein cholesterol (also known as bad cholesterol or LDL-C), was approved by the U.S. Food and Drug Administration. It requires two doses yearly after an initial dose and one every three months (FDA).

A few of the players in the lipid regulators market are"

• Pfizer Inc.
• AstraZeneca plc
• Merck & Co., Inc.
• Novartis AG
• Sanofi S.A.
• Amgen Inc.
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy’s Laboratories Ltd.
• Cipla Limited

Global Lipid Regulators Market is Segmented as Below:

By Product

• Ionizable Lipids (Lipid Nano Particles)
  • mRNA
  • siRNA
  • Others
• Triglycerides
• Sphingolipids
• Phospholipids
• Others

By Phase

• Clinical
• Pre-clinical
• Others

By Application

• Pharmaceuticals
• Vaccines and Drugs
• Scientific Research
• Nutrition & Supplements
• Food & Beverages
• Others

By Region

• North America
• Europe
• Asia Pacific
• LAMEA